BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards

We’re thrilled to announce that BillionToOne has been named the Diagnostics Company of the Year by the BioTech Breakthrough Awards!This recognition not only validates our innovative approach to molecular diagnostics, but also showcases our team’s relentless commitment to advancing healthcare through breakthrough solutions.

Related News

View All

Media Coverage

BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards

Read Article

Press Releases

Leading Molecular Diagnostics Company BillionToOne Announces Three Executive Appointments Amid Rapid Growth

Read Article

Media Coverage

The Green Room Podcast from Obstetrics & Gynecology-Interview with Jennifer Hoskovec, MS, author of “Cell-Free DNA Analysis for the Determination of Fetal Red Blood Cell Antigen Genotype in Individuals With Alloimmunized Pregnancies.”

Read Article

Media Coverage

A Major Addition to Austin’s Life Science Ecosystem with the Expansion of BillionToOne

Read Article

Press Releases

Category Defining Molecular Diagnostics Company BillionToOne Further Solidifies its Long-Term Position by Securing $140 Million Non-Dilutive Financing with Oberland Capital

Read Article

Press Releases

BillionToOne Announces Green Journal Publication that Underscores the Role of cell-free DNA NIPT for Fetal Red Blood Cell Antigen Genotyping

Read Article

Media Coverage

Slice of Healthcare-BillionToOne Raises $130M In Series D Funding Round

Read Article

Media Coverage

Genomeweb-BillionToOne Raises $130M in Series D Financing Round

Read Article

Media Coverage

Axios-BillionToOne raises $130M at $1B-plus valuation

Read Article

Press Releases

Leading Molecular Diagnostics Company BillionToOne Raises $130 Million in Oversubscribed Series D Funding Over $1B+ Valuation

Read Article

Related News

Get more news sent directly to your inbox.